Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 09, 2015 10:40 PM ET


Company Overview of Oryzon Genomics S.A.

Company Overview

Oryzon Genomics S.A., a biopharmaceutical company, develops and commercializes biomarkers identified through genomics and proteomics in the fields of diagnostics, personalized medicine, and therapy. Its products pipeline comprises GynEC-DX, a diagnostic test for endometrial cancer; ColoBRAF, a genetic test that verifies the presence of the BRAF-V600E mutation in MSI-H tumors; and Cxbladder, a non-invasive bladder cancer diagnostic test. The company also develops small molecules and monoclonal antibodies for various indications, including leukemia and other cancers, PD/AD and other dementias, Huntington, viral infections, squamous cell cancer, prostate cancer, and endometrial cancer. In addit...

Sant Ferran 74

Cornellà de Llobregat

Barcelona,  08940


Founded in 2000


34 93 515 13 13


34 93 377 40 28

Key Executives for Oryzon Genomics S.A.

Co-Founder, Chairman, Chief Executive Officer, President and Member of Financial Advisory Board
Co-Founder, Scientific Director and Director
Global Chief Financial Officer, Executive Vice President, Director and Chairman of Audit Committee
Chief Intellectual Property Officer
Director of Business Development
Compensation as of Fiscal Year 2015.

Oryzon Genomics S.A. Key Developments

Oryzon Genomics S.A. Is Planning IPO

Oryzon Genomics S.A. is seeking investment through an Initial Public Offer on National Securities Market Commission by end of this year. The firm has engaged Solventis A.V., S.A. to coordinate the investment banking and registration listing process. The company also plans to float in Nasdaq by a dual listing in the midterm.

ORYZON Presents at Rodman & Renshaw 17th Annual Global Investment Conference, Sep-08-2015

ORYZON Presents at Rodman & Renshaw 17th Annual Global Investment Conference, Sep-08-2015 . Venue: The St. Regis Hotel, Two East 55th Street, New York, NY 10022, United States.

Oryzon Genomics S.A., Special/Extraordinary Shareholders Meeting, Sep 14, 2015

Oryzon Genomics S.A., Special/Extraordinary Shareholders Meeting, Sep 14, 2015., at 10:00 Central European Standard Time. Location: registered officeSant Ferran, 74. Agenda: To consider the number of members of the Board of Directors; to consider an appointment and renewal of directors; to consider an approval extent, if any, of the application for admission to trading of the shares of the Company in the continuous market; to consider an determination, where appropriate, the maximum amount of the annual remuneration to be paid to all members of the Board of Directors in financial year 2015; to consider an delegation to the Board of Directors the power to increase capital social under the terms of Article 297.1.b) of the Corporations Act; to consider an Delegation of powers; and to consider an reading and approval, if applicable, of the minutes.

Similar Private Companies By Industry

Company Name Region
Aptus Biotech, S.L. Europe
Phytoplant Research S.L. Europe
Savia Biotech, S.A. Europe
A.S.A.C. Pharmaceutical I.A.E. Europe

Recent Private Companies Transactions

Private Placement
August 7, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Oryzon Genomics S.A., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at